



Curriculum Vitae

Personal information **Esther Brandon**

Work experience

1. Employer: Medicines Evaluation Board
 - Start date: 07-2014
 - End date:
 - Position: Kinetic Assessor
 - Activities: assessment of the clinical kinetics; assessment of in vitro metabolism and transporter studies; assessment of PBPK, PK of nanomedicines, PK of viral vectors and Drug_Drug Interactions
 - Country: Netherlands
2. Employer: National Institute for Public Health and the Environment
 - Start date: 07-2004
 - End date: 02-2017
 - Position: pharmacokineticist/toxicologist
 - Activities: kinetics of chemicals
 - Country: Netherlands

Education and training

1. Subject: CR_Appliance
 1. Start date: 05-2024
 2. End date: 05-2024
 3. Qualification: Marbach DDI workshop 2022
 4. Organisation: DDIs
 5. Country: Germany
2. Subject: CR_Appliance
 1. Start date: 05-2023
 2. End date: 05-2023
 3. Qualification: Marbach DDI workshop 2022
 4. Organisation: DDIs
 5. Country: Germany
3. Subject: CR_Appliance
 - Start date: 05-2022
 - End date: 05-2022
 - Qualification: Marbach DDI workshop 2022
 - Organisation: DDIs
 - Country: Germany
4. Subject: CR_Appliance
 - Start date: 062021
 - End date: 062021
 - Qualification: Marbach DDI workshop 2021
 - Organisation: DDIs
 - Country: Germany
5. Subject: ISSX
 - Start date: 06-2017
 - End date: 06-2017
 - Qualification: 14th European ISSX Meeting
 - Organisation: innovative science relating to the disposition, metabolism and biological effects of drugs and other xenobiotics
 - Country: Germany
6. Subject: CR_Appliance
 - Start date: 05-2018
 - End date: 05-2018
 - Qualification: DDI workshop
 - Organisation: 9th International Marbach Castle DDI Workshop
 - Country: Germany
7. Subject: Udenaes Consulting
 - Start date: 10-2019
 - End date: 102-019
 - Qualification: BBB Course
 - Organisation: insights on role and functions of the Blood_Brain Barrier (BBB) and intra_brain distribution in research concerning drug development regarding drugs aimed for a target within the CNS or drugs aimed to stay outside of the CNS, and will address also CNS drug delivery and CNS diseases. It provides in depth insight in the complex function of the BBB with regard to transport kinetics in health and disease.
 - Country: Sweden
8. Subject: CR_Appliance
 - Start date: 05-2016
 - End date: 05-2016
 - Qualification: DDI workshop
 - Organisation: 7th International Marbach Castle DDI Workshop
 - Country: Germany
9. Subject: CR_Appliance

- Start date: 05-2015
 - End date: 05-2015
 - Qualification: DDI workshop
 - Organisation: 6th International Marbach Castle DDI Workshop
 - Country: Germany
10. Subject: SIMCYP
- Start date: 10-2015
 - End date: 10-2015
 - Qualification: Simcyp Workshop for Regulators
 - Organisation: PBPK modelling
 - Country: United Kingdom
11. Subject: CR_Appliance
- Start date: 05-2014
 - End date: 05-2014
 - Qualification: DDI workshop
 - Organisation: 5th International Marbach Castle DDI Workshop
 - Country: Germany
12. Subject: Utrecht University
- Start date: 06-2000
 - End date: 06-2004
 - Qualification: PhD
 - Organisation: Drug metabolism of novel marine anti_cancer drugs
 - Country: Netherlands
13. Subject: Leiden University
- Start date: 09-1995
 - End date: 05-2000
 - Qualification: MSc
 - Organisation: Biopharmaceutical Sciences
 - Country: Netherlands
14. Subject: EMA
- Start date: 02-2013
 - End date: 02-2013
 - Qualification: Interaction guideline
 - Organisation: EMA training on the current Drug_Drug Interaction guideline
 - Country: United Kingdom
15. Subject: CR_Appliance
- Start date: 05-2013
 - End date: 05-2013
 - Qualification: DDI workshop
 - Organisation: 4th International Marbach Castle DDI Workshop
 - Country: Germany
16. Subject: CR_Appliance
- Start date: 05-2012
 - End date: 05-2012
 - Qualification: DDI workshop
 - Organisation: 3rd International Marbach Castle DDI Workshop
 - Country:
17. Subject: Different Dutch universities and the Netherlands Society of Toxicology
- Start date: 2001
 - End date: 2011
 - Qualification: Toxicologist
 - Organisation: Training and courses to become a registered toxicologist (see <http://www.toxcourses.nl/>)
 - Country: Netherlands

Additional information

Publications

- Bogaard L, Tsoi K, van de Steeg B, Brandon EFA, Geers L, van Herwaarden M, Jansman F, Maas D, Monster-Simons M, Ong DSY, Borgsteede SD. A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions. *Front Pharmacol*. 2024 Sep 30:15
- Gibb H, Devleeschauwer B, Bolger PM, Wu F, Ezendam J, Cliff J, Zeilmaker M, Verger P, Pitt J, Baines J, Adegoke G, Afshari R, Liu Y, Bokkers B, van Loveren H, Mengelers M, Brandon E, Havelaar AH, Bellinger D. World Health Organization estimates of the global and regional disease burden of four foodborne chemical toxins, 2010: a data synthesis. *F1000Res*. 2015 Dec 3;4:1393.
- Brandon EF, van Kesteren PC, van Eijkeren JC, Tienstra M, Sanchez PL, Tonk EC, Piersma AH, Bos PM. Implementation of toxicokinetics in toxicity studies Toxicokinetics of 4_methylanisole and its metabolites in juvenile and adult rats. *Regul Toxicol Pharmacol*. 2015; 73 (1): 55_64.
- Brandon EF, Janssen PJ, de Wit_Bos L. Arsenic: bioaccessibility from seaweed and rice, dietary exposure calculations and risk assessment. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess*. 2014; 31 (12): 1993_2003.
- Geraets L, Oomen AG, Krystek P, Jacobsen NR, Wallin H, Laurentie M, Verharen HW, Brandon EF, de Jong WH. Tissue distribution and elimination after oral and intravenous administration of different titanium dioxide nanoparticles in rats. *Part Fibre Toxicol*. 2014; 11: 30_.
- Brandon EF, Bakker MI, Kramer E, Bouwmeester H, Zuidema T, Alewijn M. Bioaccessibility of vitamin A, vitamin C and folic acid from dietary supplements, fortified food and infant formula. *Int J Food Sci Nutr*. 2014; 65 (4): 426_35.
- Brandon EF, Bulder AS, van Engelen JG, Mahieu CM, Mennes WC, Pronk ME, Rietveld AG, van de Ven BM, Ten Voorde SE, Wolterink G, Slob W, Zeilmaker MJ, Bessems JG. Does EU legislation allow the use of the Benchmark dose (BMD) approach for risk assessment? *Regul. Toxicol. Pharmacol*. 2013; 67 (2): 182_188.
- Brandon EFA, Baars AJ, te Biesebeek JD, Oomen AG, Bakker MI, de Heer C. Risk assessment of patulin intake from apple containing products by young children. *World Mycotoxin J*. 2012; 5 (4): 391_403,.
- Wragg J, Cave M, Basta N, Brandon E, Casteel S, Denys S, Gron C, Oomen A, Reimer K, Tack K, van de Wiele T. An inter-laboratory trial of the unified BARGE bioaccessibility method for arsenic, cadmium and lead in soil. *Sci. Total Environ*. 2011; 409: 4016_4030.
- Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers_Loustau A, Aptula A, Bai_Price A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felton S, Grignard E, Gundert_Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Leite SB, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhrer S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tähti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM. Alternative (non_animal) methods for cosmetics testing: current status and future prospects_2010. *Arch. Toxicol*. 2011; 85: 367_485.

Hoogenboom LA, Mulder PP, Zeilmaker MJ, van den Top HJ, Rummelink GJ, Brandon EF, Klijnstra M, Meijer GA, Schothorst R, Van Egmond HP. Carry_over of pyrrolizidine alkaloids from feed to milk in dairy cows. Food Addit. Contam. Part A 2011; 28: 359_372.

Goicoechea E, Brandon EF, Blokland MH, Guillén MD. Fate in digestion in vitro of several food components, including some toxic compounds coming from omega_3 and omega_6 lipids. Food Chem. Toxicol. 2011; 49: 115_124.

Brandon EF, Hermsen HP, van Eijkeren JC, Tiesjema B. Effect of administration route on the biodistribution and shedding of replication_deficient AAV2: a qualitative modelling approach. Curr. Gene Ther. 10: 91_106, 2010.

Tiesjema B, Hermsen HP, van Eijkeren JC, Brandon EF. Effect of administration route on the biodistribution and shedding of replication_deficient HAdV_5: a qualitative modelling approach. Curr. Gene Ther. 10:107_127, 2010.

Jacobs MN, Janssens W, Bernauer U, Brandon E, Coecke S, Combes R, Edwards P, Freidig A, Freyberger A, Kolanczyk R, Mc Ardle C, Mekenyan O, Schmieder P, Schrader T, Takeyoshi M, van der Burg B. The use of metabolising systems for in vitro testing of endocrine disruptors. Curr. Drug Metab. 9: 796_826, 2008.

Brandon EFA, Sparidans RW, van Ooijen RD, Meijerman I, López Lázaro L, Beijnen JH, Schellens JHM. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti_cancer drug. Invest. New Drugs 25: 9_19, 2007.

Brandon EFA, Bosch TM, Deenen MJ, Levink R, van der Wal E, van Meerveld JBM, Bijl M, Beijnen JH, Schellens JHM, Meijerman I. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV_1) and colon carcinoma (CaCo_2, LS180) cell lines. Toxicol. Appl. Pharmacol. 211: 1_10, 2006.

Brandon EFA, Sparidans RW, Guijt K._J., Löwenthal S, Meijerman I, López Lázaro L., Manzanares I, Beijnen JH, Schellens JHM. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET 743 (Yondelis®, Trabectedin®), a novel marine anti_cancer drug. Invest. New Drugs 24: 3_14, 2006.

Brandon EFA, Meijerman I, Klijn JS, de Arend D, Sparidans RW, López Lázaro LL, Beijnen JH, Schellens JHM. In vitro cytotoxicity of ET_743 (Trabectedin®, Yondelis®), a marine anti_cancer drug, in the Hep G2 cell line; influence of cytochrome P450 and phase II inhibition and cytochrome P450 induction. Anticancer Drugs 16: 935_943, 2005.

Brandon EFA, van Ooijen RD, Sparidans RW, Heck AJR, Beijnen JH, Schellens JHM. Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. J. Mass Spectrom. 40: 821_831, 2005.

Brandon EFA, Sparidans RW, Meijerman I, Manzanares I, Beijnen JH, Schellens JHM. In vitro characterization of the biotransformation pathway of thiocoraline, a novel marine anti_cancer drug. Invest. New Drugs 22: 241_251, 2004.

Brandon EFA, Raap CD, Meijerman I, Beijnen JH, Schellens JHM. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 189: 233_246, 2003.

Projects

drug-herbal interactions
P-gp intestinal interactions

Memberships

Other Relevant Information